echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Biotech BAT7104 Injection Obtained Clinical Trial Approval Notice

    Biotech BAT7104 Injection Obtained Clinical Trial Approval Notice

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 19, Biotech issued an announcement stating that the company had recently received the "Clinical Trial Approval Notice" for the company's drug BAT7104 injection, which was approved and issued by the National Medical Products Administration
    .

    BAT7104 is a bispecific antibody against PD-L1 and CD47 developed by Biotech, which is intended to be developed for tumor treatment
    .


    BAT7104 activates macrophages to phagocytose tumor cells by blocking the CD47/SIRPα pathway; BAT7104 blocks the PD-L1/PD-1 pathway to relieve tumor cells from inhibiting T cells through the PD-L1/PD-1 pathway, and achieve T The combined anti-tumor effect of cells and macrophages


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.